Yet Another Value Podcast
Andrew Walker
Yet Another Value Podcast is a new podcast from Andrew Walker, the founder of yetanothervalueblog.com/. We interview top investors and dive deep into stocks and companies they are currently working on and investing in. While nothing on this channel is investing advice and everyone should do their own diligence, our goal is to frequently feature edgy and actionable value and/or event driven ideas.
Please see our legal and disclaimer at: https://yetanothervalueblog.substack.com/p/legal-and-disclaimer
Please see our legal and disclaimer at: https://yetanothervalueblog.substack.com/p/legal-and-disclaimer
Episodes
Mentioned books
Mar 29, 2026 • 47min
Theravance's strategic review with Andy Summers $TBPH
Andy Summers, CIO of Summers Value and value investor, joins to analyze Theravance after a Phase 3 setback. He discusses Yupelri’s royalty potential, balance sheet strength and cost cuts. They explore strategic review dynamics, potential buyers and China upside. The conversation highlights valuation assumptions, downside scenarios and why the situation may offer asymmetric risk-reward.
9 snips
Mar 27, 2026 • 50min
Night Watch's Roderick van Zuylen on Marex $MRX
Roderick van Zuylen, an investment pro at Night Watch focused on event-driven and value strategies, joins to dissect Marex. He explains Marex’s FCM role, why consolidation and acquisitions boost returns, and how rising volumes help the business. They also tackle industry risks like credit exposure, interest rate sensitivity, and a recent short report.
9 snips
Mar 25, 2026 • 27min
March 2026 Random Ramblings
They dig into odd market behavior where index moves hide extreme single-stock swings. The conversation highlights how a long software and growth tailwind shaped investor track records. A three-year reassessment rule for stagnant holdings is revisited, with caveats for cyclical sectors. Practical talk on position sizing, re-underwriting after big moves, and using cost limits to avoid dangerous doubling down.
Mar 23, 2026 • 1h 12min
Adam May on investing in biotech $NKTR $ABVX
Adam May, a practicing dermatologist and former small-cap biotech fund manager, explains how he finds mispriced biotech opportunities. He discusses NKTR’s trial nuances, maintenance data, and commercial vs buyout paths. He also covers ABVX’s skeptical backstory, the decisive slide that changed the math, and why maintenance results made it acquirable.
7 snips
Mar 20, 2026 • 47min
Chris Paryse on Ferrellgas's big conversion $FGPR
Chris Paryse, a special situations investor focused on distressed and complex capital structures, unpacks Ferrellgas’s post-bankruptcy makeover. He explains the Class B-to-A conversion and its free-float impact. Short sentences cover deleveraging paths, preferreds and leverage, relisting/liquidity as a catalyst, and dividend reinstatement possibilities.
9 snips
Mar 14, 2026 • 58min
Accrued Interest's Simeon McMillan on $VSNT and the evolving media space
Simeon McMillan, a media analyst and former senior operator at major media companies, breaks down the shifting media landscape. He discusses Comcast’s Versant spin-off and why 2028 matters. Short takes cover CNBC’s trophy status, Golf Now’s hidden value, YouTube’s impact on viewing and carriage fights, and how sports-rights and streaming economics reshape valuations.
14 snips
Mar 10, 2026 • 1h 1min
A tour through the media landscape with TSOH's Alex Morris
Alex Morris, writer of The Science of Hitting and media-focused investor, breaks down the shifting streaming landscape. He covers Netflix’s failed Warner Bros bid and strategic aftermath. Conversation jumps to AI’s impact on IP, the messy economics of sports rights, and the challenges of integrating large media platforms.
12 snips
Mar 9, 2026 • 51min
Carriage House's Will Cleary on $FTAI
Will Cleary, an investment professional at Carriage House Fund focused on concentrated value investing, discusses FTAI Aviation’s transformation into a vertically integrated engine maintenance and module-swap platform. He covers how module swaps cut time and cost, FTAI’s feedstock and network effects, the Strategic Capital Initiative, responses to a short report, valuation thinking, and repurposing engines into turbines for data centers.
Mar 3, 2026 • 58min
Roy Swisa on $DJCO
Roy Swisa, a value investor and researcher who consulted for Daily Journal, joins to discuss his work on Journal Technologies and how niche, compliance‑heavy software earns durable moats. He covers primary research tactics, using RFPs and AI to track product shifts, the sum‑of‑the‑parts valuation of a complex company, and how procurement, proprietary data, and incentives shape vertical SaaS outcomes.
19 snips
Feb 24, 2026 • 55min
Investing in Biotech with Verdad Capital
Greg Obenshain, partner at Verdad Capital who builds biotech-specific quantitative signals, and Dan Rasmussen, partner and contrarian value researcher, discuss quantitative investing in biotech. They cover specialist fund ownership as a quality signal. They explore insider buying, spending-based valuation metrics, momentum within therapeutic categories, and short-side risk management through diversification and rebalancing.
